Addex depression drug fails in trial, shares dive

Addex Therapeutics' (ADDXF) ADX71149 treatment for anxious depression was not more effective than a placebo in a Phase IIa trial.

The results don't "support the further development of ADX71149 in anxious depression," Addex says, although the exploration of the drug for other purposes "remains of potential interest."

Johnson & Johnson (JNJ) unit Janssen conducted the trial.

The failure is a major blow, as anxious depression is a leading cause of disability worldwide.

Addex shares are -27% in Zurich. (PR)

Comments (2)
  • bernie 1
    , contributor
    Comments (682) | Send Message
    Someone please explain, does Addex belong to Janssen or it's parent JNJ? As far as I can see is that Janssen ran the trial, but why then is JNJ down (not as much as (addxf) if they only used there trial data. Am I missing something here?
    10 Feb 2014, 08:28 AM Reply Like
  • drive-by poster
    , contributor
    Comments (81) | Send Message
    JNJ is currently up .1% on the day. Big company, many, many factors moving the stock.
    10 Feb 2014, 10:43 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs